Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
ES |
|
Native Mineral Resources Holdings Ltd
ASX:NMR
|
AU |
Intrinsic Value
The intrinsic value of Laboratorios Farmaceuticos ROVI SA (ROVI) under the Base Case is 55.83 EUR per share.
Compared with the current market price of 58.5 EUR, the stock appears
Overvalued by 5% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Laboratorios Farmaceuticos ROVI Does
Laboratorios Farmacéuticos ROVI is a Spanish drug maker that sells prescription medicines and also manufactures medicines for other pharmaceutical companies. Its own products are mainly used in hospitals and in treatments for conditions such as blood-clotting disorders and some central nervous system diseases. It also makes and sells heparin-based medicines and related ingredients, which are widely used in anticoagulant treatment.
- Headquarters
- Spain ES
- Employees
- 1 998
- IPO date
- Oct 26, 2007
Laboratorios Farmaceuticos ROVI has a narrow economic moat
Laboratorios Farmaceuticos ROVI SA has a narrow economic moat, offering limited protection against competitors and some ability to sustain profitability.
Read the full moat analysis
Revenue & Expenses Breakdown
Laboratorios Farmaceuticos ROVI SA
Earnings Waterfall
Laboratorios Farmaceuticos ROVI SA
The intrinsic value for Laboratorios Farmaceuticos ROVI SA (ROVI) under the Base Case is 55.83 EUR.
Compared with the current market price of 58.5 EUR, the stock appears Overvalued by 5% .